Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma

Matthew D. Galsky, Noah M. Hahn, Bryan Wong, Karen M. Lee, Pamela Argiriadi, Costantine Albany, Kiev Gimpel-Tetra, Nancy Lowe, Mohamed Shahin, Vaibhav Patel, Che Kai Tsao, William K. Oh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: The purpose of this investigator-initiated multicenter phase II study was to determine the activity of the third-generation synthetic anthracycline, amrubicin, administered as second-line therapy in patients with advanced urothelial carcinoma. Methods: Patients with progressive metastatic urothelial cancer despite first-line chemotherapy were eligible for enrollment. Amrubicin was initially administered at a dose of 40 mg/m2/day daily × 3 every 21 days, and the dose was subsequently reduced to 35 mg/m2/day daily × 3 every 21 days. Prophylactic granulocyte colony-stimulating factor was administered to all patients, and prophylactic antibiotics were administered to patients at high risk of febrile neutropenia. Treatment was administered for up to six cycles in the absence of intolerable toxicity or disease progression. The primary endpoint was the objective response rate. Results: A total of 22 patients were enrolled. Among the first three patients enrolled, all developed grade 4 neutropenia and one patient died of neutropenic sepsis. The starting dose of amrubicin was subsequently reduced, there were no further episodes of febrile neutropenia, and only one patient required a subsequent dose reduction. The most common adverse events were hematologic; grade ≤3 neutropenia occurred in 27 %, and other grade ≤3 adverse events were uncommon. Partial responses were achieved in three patients [13.6, 95 % confidence interval (CI) 0-28 %), while stable disease was the best response in 12 patients (54.5, 95 % CI 33.7-75.3 %). The trial was closed prematurely due to a development decision by the funder. Conclusions: Amrubicin as second-line therapy in advanced urothelial carcinoma is associated with modest single-agent activity. While there remains a role for the introduction of novel cytotoxic agents in the management of metastatic urothelial cancer, optimal development of such therapies will likely require patient selection biomarkers.

Original languageEnglish (US)
Pages (from-to)1259-1265
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume76
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

Topoisomerase II Inhibitors
Carcinoma
Chemotherapy
Anthracyclines
Cytotoxins
Biomarkers
Granulocyte Colony-Stimulating Factor
Therapeutics
Febrile Neutropenia
Toxicity
Neutropenia
Anti-Bacterial Agents
amrubicin
Confidence Intervals
Patient Selection
Disease Progression
Neoplasms
Sepsis
Research Personnel

Keywords

  • Amrubicin
  • Anthracyclines
  • Bladder cancer
  • Chemotherapy
  • Metastatic
  • Urothelial cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. / Galsky, Matthew D.; Hahn, Noah M.; Wong, Bryan; Lee, Karen M.; Argiriadi, Pamela; Albany, Costantine; Gimpel-Tetra, Kiev; Lowe, Nancy; Shahin, Mohamed; Patel, Vaibhav; Tsao, Che Kai; Oh, William K.

In: Cancer Chemotherapy and Pharmacology, Vol. 76, No. 6, 01.12.2015, p. 1259-1265.

Research output: Contribution to journalArticle

Galsky, MD, Hahn, NM, Wong, B, Lee, KM, Argiriadi, P, Albany, C, Gimpel-Tetra, K, Lowe, N, Shahin, M, Patel, V, Tsao, CK & Oh, WK 2015, 'Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma', Cancer Chemotherapy and Pharmacology, vol. 76, no. 6, pp. 1259-1265. https://doi.org/10.1007/s00280-015-2884-7
Galsky, Matthew D. ; Hahn, Noah M. ; Wong, Bryan ; Lee, Karen M. ; Argiriadi, Pamela ; Albany, Costantine ; Gimpel-Tetra, Kiev ; Lowe, Nancy ; Shahin, Mohamed ; Patel, Vaibhav ; Tsao, Che Kai ; Oh, William K. / Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. In: Cancer Chemotherapy and Pharmacology. 2015 ; Vol. 76, No. 6. pp. 1259-1265.
@article{ff05b34b27dc4f0da971de0112f2835f,
title = "Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma",
abstract = "Purpose: The purpose of this investigator-initiated multicenter phase II study was to determine the activity of the third-generation synthetic anthracycline, amrubicin, administered as second-line therapy in patients with advanced urothelial carcinoma. Methods: Patients with progressive metastatic urothelial cancer despite first-line chemotherapy were eligible for enrollment. Amrubicin was initially administered at a dose of 40 mg/m2/day daily × 3 every 21 days, and the dose was subsequently reduced to 35 mg/m2/day daily × 3 every 21 days. Prophylactic granulocyte colony-stimulating factor was administered to all patients, and prophylactic antibiotics were administered to patients at high risk of febrile neutropenia. Treatment was administered for up to six cycles in the absence of intolerable toxicity or disease progression. The primary endpoint was the objective response rate. Results: A total of 22 patients were enrolled. Among the first three patients enrolled, all developed grade 4 neutropenia and one patient died of neutropenic sepsis. The starting dose of amrubicin was subsequently reduced, there were no further episodes of febrile neutropenia, and only one patient required a subsequent dose reduction. The most common adverse events were hematologic; grade ≤3 neutropenia occurred in 27 {\%}, and other grade ≤3 adverse events were uncommon. Partial responses were achieved in three patients [13.6, 95 {\%} confidence interval (CI) 0-28 {\%}), while stable disease was the best response in 12 patients (54.5, 95 {\%} CI 33.7-75.3 {\%}). The trial was closed prematurely due to a development decision by the funder. Conclusions: Amrubicin as second-line therapy in advanced urothelial carcinoma is associated with modest single-agent activity. While there remains a role for the introduction of novel cytotoxic agents in the management of metastatic urothelial cancer, optimal development of such therapies will likely require patient selection biomarkers.",
keywords = "Amrubicin, Anthracyclines, Bladder cancer, Chemotherapy, Metastatic, Urothelial cancer",
author = "Galsky, {Matthew D.} and Hahn, {Noah M.} and Bryan Wong and Lee, {Karen M.} and Pamela Argiriadi and Costantine Albany and Kiev Gimpel-Tetra and Nancy Lowe and Mohamed Shahin and Vaibhav Patel and Tsao, {Che Kai} and Oh, {William K.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s00280-015-2884-7",
language = "English (US)",
volume = "76",
pages = "1259--1265",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma

AU - Galsky, Matthew D.

AU - Hahn, Noah M.

AU - Wong, Bryan

AU - Lee, Karen M.

AU - Argiriadi, Pamela

AU - Albany, Costantine

AU - Gimpel-Tetra, Kiev

AU - Lowe, Nancy

AU - Shahin, Mohamed

AU - Patel, Vaibhav

AU - Tsao, Che Kai

AU - Oh, William K.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Purpose: The purpose of this investigator-initiated multicenter phase II study was to determine the activity of the third-generation synthetic anthracycline, amrubicin, administered as second-line therapy in patients with advanced urothelial carcinoma. Methods: Patients with progressive metastatic urothelial cancer despite first-line chemotherapy were eligible for enrollment. Amrubicin was initially administered at a dose of 40 mg/m2/day daily × 3 every 21 days, and the dose was subsequently reduced to 35 mg/m2/day daily × 3 every 21 days. Prophylactic granulocyte colony-stimulating factor was administered to all patients, and prophylactic antibiotics were administered to patients at high risk of febrile neutropenia. Treatment was administered for up to six cycles in the absence of intolerable toxicity or disease progression. The primary endpoint was the objective response rate. Results: A total of 22 patients were enrolled. Among the first three patients enrolled, all developed grade 4 neutropenia and one patient died of neutropenic sepsis. The starting dose of amrubicin was subsequently reduced, there were no further episodes of febrile neutropenia, and only one patient required a subsequent dose reduction. The most common adverse events were hematologic; grade ≤3 neutropenia occurred in 27 %, and other grade ≤3 adverse events were uncommon. Partial responses were achieved in three patients [13.6, 95 % confidence interval (CI) 0-28 %), while stable disease was the best response in 12 patients (54.5, 95 % CI 33.7-75.3 %). The trial was closed prematurely due to a development decision by the funder. Conclusions: Amrubicin as second-line therapy in advanced urothelial carcinoma is associated with modest single-agent activity. While there remains a role for the introduction of novel cytotoxic agents in the management of metastatic urothelial cancer, optimal development of such therapies will likely require patient selection biomarkers.

AB - Purpose: The purpose of this investigator-initiated multicenter phase II study was to determine the activity of the third-generation synthetic anthracycline, amrubicin, administered as second-line therapy in patients with advanced urothelial carcinoma. Methods: Patients with progressive metastatic urothelial cancer despite first-line chemotherapy were eligible for enrollment. Amrubicin was initially administered at a dose of 40 mg/m2/day daily × 3 every 21 days, and the dose was subsequently reduced to 35 mg/m2/day daily × 3 every 21 days. Prophylactic granulocyte colony-stimulating factor was administered to all patients, and prophylactic antibiotics were administered to patients at high risk of febrile neutropenia. Treatment was administered for up to six cycles in the absence of intolerable toxicity or disease progression. The primary endpoint was the objective response rate. Results: A total of 22 patients were enrolled. Among the first three patients enrolled, all developed grade 4 neutropenia and one patient died of neutropenic sepsis. The starting dose of amrubicin was subsequently reduced, there were no further episodes of febrile neutropenia, and only one patient required a subsequent dose reduction. The most common adverse events were hematologic; grade ≤3 neutropenia occurred in 27 %, and other grade ≤3 adverse events were uncommon. Partial responses were achieved in three patients [13.6, 95 % confidence interval (CI) 0-28 %), while stable disease was the best response in 12 patients (54.5, 95 % CI 33.7-75.3 %). The trial was closed prematurely due to a development decision by the funder. Conclusions: Amrubicin as second-line therapy in advanced urothelial carcinoma is associated with modest single-agent activity. While there remains a role for the introduction of novel cytotoxic agents in the management of metastatic urothelial cancer, optimal development of such therapies will likely require patient selection biomarkers.

KW - Amrubicin

KW - Anthracyclines

KW - Bladder cancer

KW - Chemotherapy

KW - Metastatic

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=84947552272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947552272&partnerID=8YFLogxK

U2 - 10.1007/s00280-015-2884-7

DO - 10.1007/s00280-015-2884-7

M3 - Article

C2 - 26464352

AN - SCOPUS:84947552272

VL - 76

SP - 1259

EP - 1265

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -